Literature DB >> 20150647

Primary effusion lymphoma in two HIV-negative patients successfully treated with pleurodesis as first-line therapy.

X Yiakoumis1, G A Pangalis, M-C Kyrtsonis, T P Vassilakopoulos, F N Kontopidou, C Kalpadakis, P Korkolopoulou, G Levidou, A Androulaki, M P Siakantaris, S Sachanas, A Andreopoulos.   

Abstract

Primary effusion lymphoma (PEL) is a rare non-Hodgkin's lymphoma (NHL) mostly occurring in HIV-positive patients. It is characterized by the development of effusion in one or more body cavities, with no tumor masses and a positive human herpes virus-8 (HHV8) status. It has a poor survival profile and no optimal treatment is yet defined. We report two HIV-negative, HHV8-positive patients with PEL of the pleural cavity who achieved a durable remission after pleurodesis with bleomycin and no systemic therapy. We also perform a review of the relevant literature regarding the clinical data, treatment, and survival of PEL in HIV-negative patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20150647

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.

Authors:  William R Foster; Alina Bischin; Russell Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-01

2.  Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease.

Authors:  Elchanan Nussinson; Fahmi Shibli; Azmi Shahbari; Wasseem Rock; Mazen Elias; Irit Elmalah
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

3.  Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers.

Authors:  Dirk P Dittmer; Kristy L Richards; Blossom Damania
Journal:  Front Microbiol       Date:  2012-04-18       Impact factor: 5.640

4.  Human Immunodeficiency Virus (HIV)-Negative and Human Herpes Virus-8 (HHV-8)-Positive Primary Effusion Lymphoma: A Case Report and Review of the Literature.

Authors:  Sonay Güven Karataş; Reyhan Bayrak; Ozlem Sahin Balçık; Kadir Serkan Yalçın; Esra Atıcı; Umit Akyıldız; Ali Koşar
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

5.  Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report.

Authors:  Lynnette K Tumwine; Rejani Lalitha; Claudio Agostinelli; Simon Luzige; Jackson Orem; Pier Paolo Piccaluga; Lawrence O Osuwat; Stefano A Pileri
Journal:  J Med Case Rep       Date:  2011-02-14

6.  New insights into malignant B-cell disorders.

Authors:  Marie-Christine Kyrtsonis; Kazuyuki Shimizu; Panayiotis Panayiotidis; Gerassimos A Pangalis
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

Review 7.  Classic KSHV/HHV-8-positive Primary Effusion Lymphoma (PEL): A Systematic Review and Meta-Analysis of Case Reports.

Authors:  Ilaria Cozzi; Giovanni Rossi; Emma Rullo; Valeria Ascoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-03-01       Impact factor: 2.576

8.  Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma.

Authors:  Kenta Hayashino; Yusuke Meguri; Ryouya Yukawa; Aya Komura; Makoto Nakamura; Chikamasa Yoshida; Kazuhiko Yamamoto; Wakako Oda; Kenji Imajo
Journal:  Int J Hematol       Date:  2022-09-06       Impact factor: 2.319

9.  An unusual case of Primary Effusion Lymphoma with aberrant T-cell phenotype in a HIV-negative, HBV-positive, cirrhotic patient, and review of the literature.

Authors:  Charitini Nepka; Dimitrios Kanakis; Maria Samara; Andreas Kapsoritakis; Spyridon Potamianos; Maria Karantana; Georgios Koukoulis
Journal:  Cytojournal       Date:  2012-06-29       Impact factor: 2.091

Review 10.  Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas.

Authors:  Jungang Chen; Samantha Kendrick; Zhiqiang Qin
Journal:  Viruses       Date:  2019-12-16       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.